Celecoxib in Parkinson Disease as Adjuvant Therapy

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

NCT Number	NCT07246278
Lead Sponsor	Tanta University
Conditions	Parkinson Disease
Enrollment	80 participants
Start Date	2025-11-20
Primary Completion	2026-11-20 (estimated)
Study Completion	2026-11-28 (estimated)
Updated on ClinicalTrials.gov	2025-12-05